Clinical trials of ovarian cancer blood test scheduled
This article was originally published in Clinica
Atairgin Technologies is to begin clinical trials of a blood test for ovarian cancer, which may be more sensitive than the commonly used CA125 test. The test measures blood levels of the biochemical marker lysophosphatidic acid (LPA). The presence of this marker is independent of the stage of tumour growth and may therefore provide an early detection tool, says the company.
You may also be interested in...
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.